Literature Review: Efektivitas, Keamanan, dan Biaya Terapi Imidafenacin untuk Pasien Overactive Bladder
DOI:
https://doi.org/10.26630/jk.v11i3.2256Keywords:
Critical review, Imidafenacin, Muscarinic antagonists, Overactive bladder.Abstract
Imidafenacin is a new antimuscarinic agent in Indonesia that was recently approved in 2019 to treat overactive bladder (OAB) symptoms, including urinary incontinence, urinary frequency, and urinary urgency. As a new OAB medication in the Indonesian commercial market, a comprehensive review on the efficacy, safety, and cost of imidafenacin are essentially needed to optimize the responsible use of this drug, particularly in the era of universal coverage implementation in Indonesia. This review aimed to describe the profile of imidafenacin and to compare the efficacy, safety, and cost of imidafenacin with the other antimuscarinic drugs in Indonesia, and the guideline recommendations towards when to use imidafenacin for OAB treatment. Only results from systematic reviews and meta-analyses were used in the efficacy and safety comparison. Our review found that the efficacy of imidafenacin was relatively comparable to the other antimuscarinic drugs in Indonesia, including solifenacin, tolterodine, dan propiverine. Also, a better safety profile was found in the imidafenacin group, in particular, imidafenacin caused less dry mouth and constipation. This could be attributable to the higher affinity of imidafenacin to the M3 receptor resulting in less antimuscarinic effect at the other receptors. From the cost perspective, the cost of medication by using imidafenacin was relatively lower compared to the other antimuscarinic drugs in Indonesia. It, therefore, could be suggested to use imidafenacin as a potential agent for OAB.
References
Arnold, J., McLeod, N., Thani-Gasalam, R., & Rashid, P. (2012). Overactive bladder syndrome: management and treatment options. Australian Family Physician, 14(4), 211-217. https://doi.org/10.5114/ pm.2015.56403
Badan Pengawas Obat dan Makanan Republik Indonesia. (2015a). Mictonorm. Pusat Informasi Obat Nasional. http://pionas.pom.go.id/obat-baru/mictonorm
Badan Pengawas Obat dan Makanan Republik Indonesia. (2015b). Tolterodin tartrat. Pusat Informasi Obat Nasional. http:// pionas.pom.go.id/search/node/TOLTERODINE
Badan Pengawas Obat dan Makanan Republik Indonesia. (2015c). Uritos tablet selaput 0,1mg. Pusat Informasi Obat Nasional. http://pionas.pom.go.id/obat-baru/uritos-tablet-salut-selaput-01-mg
Badan Pengawas Obat dan Makanan Republik Indonesia. (2015d). Vesicare tablet 5mg. Pusat Informasi Obat Nasional. http://pionas.pom.go.id/obat-baru/vesicare-tablet-5mg
Badan Pengawas Obat dan Makanan RI. (2019). Cek Produk BPOM. Pusat Informasi Obat Nasional. https://cekbpom.pom.go.id/index. php/home/produk/j0a3m9hov94ebj4gnajrq0aev7/all/row/10/page/1/order/4/DESC/search/5/imidafenacin
Corcos, J., Przydacz, M., Campeau, L., Gray, G., Hickling, D., Honeine, C., Radomski, S. B., Stothers, L., & Wagg, A. (2017). CUA guideline on adult overactive bladder. Canadian Urological Association Journal, 11(5), E142-E173. https://doi.org/10.5489 /cuaj.4586
Eapen, R. S., & Radomski, S. B. (2016). Review of the epidemiology of overactive bladder. Research and Reports in Urology, 8, 71-76. https://doi.org/10.2147/RRU.S102441
Gormley, E. A., Lightner, D. J., Burgio, K. L., Chai, T. C., Clemens, J. Q., Culkin, D. J., Das, A. K., Foster, H. E., Scarpero, H. M., Tessier, C. D., & Vasavada, S. P. (2012). Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. Journal of Urology, 188(6 SUPPL.), 2455–2463. https://doi.org /10.1016/j.juro.2012.09.079
Huang, W., Zong, H., Zhou, X., Wang, T., & Zhang, Y. (2015). Efficacy and safety of imidafenacin for overactive bladder in adult: a systematic review and meta-analysis. Int Urol Nephrol, 77. https://doi.org/10.1007/s12262-015-1264-1
Jayarajan, J., & Radomski, S. B. (2013). Pharmacotherapy of overactive bladder in adults: A review of efficacy, tolerability, and quality of life. Research and Reports in Urology, 6(1), 1-16. https://doi.org/10.2147 /RRU.S40034
Kobayashi, F., Yageta, Y., Segawa, M., & Matsuzawa, S. (2011). Effects of Imidafenacin (KRP-197/ONO-8025), a New Anti-cholinergic Agent, on Muscarinic Acetylcholine Receptors. Arzneimittelforsc hung, 57(02), 92–100. https://doi.org/10. 1055/s-0031-1296589
Maggiore, U. L. R., Scala, C., Venturini, P. L., & Ferrero, S. (2013). Imidafenacin for the treatment of overactive bladder. Expert Opinion on Pharmacotherapy, 14(10), 1383-1397. https://doi.org/10.1517/ 14656566.2013.796930
Nazir, J., Kelleher, C., Aballéa, S., Maman, K., Hakimi, Z., Mankowski, C., & Odeyemi, I. (2018). Comparative efficacy and tolerability of solifenacin 5 mg/day versus other oral antimuscarinic agents in overactive bladder: A systematic literature review and network meta-analysis. Neurourology and Urodynamics, 37(3), 986–996. https://doi.org/10.1002/nau.23413
Ono Pharmaceutical Co. (2010). Approval received for orally disintegrating tablet of imidafenacin (INN), a drug for overactive bladder. https://www.ono.co.jp/eng/news /pdf/sm_cn101111.pdf
Shah, D., & Badlani, G. (2002). Treatment of overactive bladder and incontinence in the elderly. Reviews in Urology, 4 Suppl 4, S38-43. http://www.ncbi.nlm.nih.gov/ pubmed/16986020%0Ahttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC1476020
Takeuchi, T., Zaitsu, M., & Mikami, K. (2013). Experience with imidafenacin in the management of overactive bladder disorder. Therapeutic Advances in Urology, 5(1), 43-58. https://doi.org/10.1177/1756287212459549
Wolff, G. F., Kuchel, G. A., & Smith, P. P. (2014). Overactive bladder in the vulnerable elderly. Research and Reports in Urology, 6, 131–138. https://doi.org/10.2147/RRU .S41843
Wu, J. P., Peng, L., Zeng, X., Li, H., Shen, H., & Luo, D. Y. (2020). Is imidafenacin an alternative to current antimuscarinic drugs for patients with overactive bladder syndrome? International Urogynecology Journal. https://doi.org/10.1007/s00192-020-04329-x
Yamada, S., Ito, Y., Nishijima, S., Kadekawa, K., & Sugaya, K. (2018). Basic and clinical aspects of antimuscarinic agents used to treat overactive bladder. Pharmacology and Therapeutics, 189, 130–148. https://doi.org/ 10.1016/j.pharmthera.2018.04.010
Downloads
Published
Issue
Section
License
Authors who publish in this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (CC BY-SA 4.0) that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors can enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
